Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.
Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, Salles G, Leblond V, Roussel M, Alakl M, Hermine O, Planche L, Harousseau JL, Fermand JP. Moreau P, et al. Among authors: leblond v. Blood. 2010 Dec 2;116(23):4777-82. doi: 10.1182/blood-2010-07-294405. Epub 2010 Aug 19. Blood. 2010. PMID: 20724537 Free article. Clinical Trial.
Evidence for naive T-cell repopulation despite thymus irradiation after autologous transplantation in adults with multiple myeloma: role of ex vivo CD34+ selection and age.
Malphettes M, Carcelain G, Saint-Mezard P, Leblond V, Altes HK, Marolleau JP, Debré P, Brouet JC, Fermand JP, Autran B. Malphettes M, et al. Among authors: leblond v. Blood. 2003 Mar 1;101(5):1891-7. doi: 10.1182/blood-2002-06-1929. Epub 2002 Oct 24. Blood. 2003. PMID: 12406891 Free article. Clinical Trial.
Best therapy for primary amyloidosis, a not-yet-solved question.
Jaccard A, Moreau P, Leblond V, Fermand JP. Jaccard A, et al. Among authors: leblond v. Blood. 2004 Nov 1;104(9):2990-1; author reply 2992-4. doi: 10.1182/blood-2004-05-1885. Blood. 2004. PMID: 15498863 Free article. No abstract available.
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.
Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN, Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L, Milpied N. Choquet S, et al. Among authors: leblond v. Blood. 2006 Apr 15;107(8):3053-7. doi: 10.1182/blood-2005-01-0377. Epub 2005 Oct 27. Blood. 2006. PMID: 16254143 Free article. Clinical Trial.
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P; Group Myelome-Autogreffe. Fermand JP, et al. Among authors: leblond v. J Clin Oncol. 2005 Dec 20;23(36):9227-33. doi: 10.1200/JCO.2005.03.0551. Epub 2005 Nov 7. J Clin Oncol. 2005. PMID: 16275936 Clinical Trial.
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.
Schönland SO, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G, Campbell A, Carreras E, Ferrant A, Grommisch L, Jacobs P, Kröger N, La Nasa G, Russell N, Zachee P, Goldschmidt H, Iacobelli S, Niederwieser D, Gahrton G; Chronic Leukemia Working Party; Myeloma Subcommittee of the European Cooperative Group for Blood and Marrow Transplantation. Schönland SO, et al. Among authors: leblond v. Blood. 2006 Mar 15;107(6):2578-84. doi: 10.1182/blood-2005-06-2462. Epub 2005 Nov 17. Blood. 2006. PMID: 16293611 Free article.
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.
Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, Garcia-Sanz R, Johnson S, Kimby E, Leblond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone MJ. Treon SP, et al. Among authors: leblond v. Blood. 2006 May 1;107(9):3442-6. doi: 10.1182/blood-2005-02-0833. Epub 2006 Jan 12. Blood. 2006. PMID: 16410453 Free article.
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP; Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup. Jaccard A, et al. Among authors: leblond v. N Engl J Med. 2007 Sep 13;357(11):1083-93. doi: 10.1056/NEJMoa070484. N Engl J Med. 2007. PMID: 17855669 Free article. Clinical Trial.
The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.
Terrier B, Jaccard A, Harousseau JL, Delarue R, Tournilhac O, Hunault-Berger M, Hamidou M, Dantal J, Bernard M, Grosbois B, Morel P, Coiteux V, Gisserot O, Rodon P, Hot A, Elie C, Leblond V, Fermand JP, Fakhouri F. Terrier B, et al. Among authors: leblond v. Medicine (Baltimore). 2008 Mar;87(2):99-109. doi: 10.1097/MD.0b13e31816c43b6. Medicine (Baltimore). 2008. PMID: 18344807 Free article.
411 results